Apollo EndosurgeryAnnounces Positive Five Year Results From LAP-BAND Pivotal Study Conducted With Lower BMI Patients

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced the results from a multicenter pivotal study detailing five-year health outcomes for LAP-BAND^® patients with a BMI between 30-39.9.

“Surgical intervention like gastric banding in this study can provide durable weight loss and significant improvements in pre-existing co-morbid conditions and quality of life in the right patients, right hands and the right places”

• The study showed sustained long term weight loss over the 5 year period. Average percent weight loss at five-years was 15.9 +/-12.4%, corresponding with 62.7% excess weight loss (EWL).
• Patients showed significant improvement in their co-morbid conditions at the end of the 5 year period strengthening the previously released data of 85.7% improvement in diabetes, 64.4% improvement in dyslipidemia, and 59.6% improvement with hypertension.
• No unanticipated adverse device events were reported.
• The device explant rate was 14.8% which was substantially below the study’s safety objective of less than 32.5% at 5 years. Excluding patients who elected to exercise their option to have the band removed at no cost to them on completion of the study, the explant rate was 5.4% at 5 years.

“Surgical intervention like gastric banding in this study can provide durable weight loss and significant improvements in pre-existing co-morbid conditions and quality of life in the right patients, right hands and the right places,” said John Morton, MD, Director of Bariatric Surgery at Stanford University Hospital and Clinics, Chief of Bariatric Surgery at Stanford University Medical Center and current President of the American Society of Metabolic and Bariatric Surgery. “This study indicates that surgical therapy like gastric banding should be considered a treatment option for patients with a BMI as low as 30 to stop or slow the progression of obesity and associated co-morbidities.”

Dennis McWilliams, President and Chief Commercial Officer of Apollo Endosurgery, added, “The LAP-BAND^® AP System is safe and effective for patients with a BMI of 30 or higher, that delivers sustained weight loss, improvements in quality of life, reduced cardiometabolic risk when combined with reasonable and proper physician follow-up with their patient.”

The five-year pivotal study, published in the International Journal of Obesity, tracked the health outcomes for 149 LAP-BAND^® patients from six U.S. states with a BMI of 30 to 39.9. Results showed that 76% of patients achieved and sustained at least 30% EWL lost during the study period which substantially exceeded the primary effectiveness endpoint of at least 40% of subjects losing at least 30% of their excess body weight. Patients were followed up after surgery eight times the first year, four times in the second year and twice per year thereafter.

Traditionally, weight loss surgery is indicated for use in weight reduction for severely obese patients with a BMI of 35 or higher while the LAP-BAND^® is approved for patients with a BMI as low as 30 with one or more severe co-morbid conditions.

About LAP-BAND^® System

The LAP-BAND^® System is placed laparoscopically in a minimally invasive procedure to assist in gradual weight loss. The LAP-BAND^® System is fastened around the top of the stomach, and works by applying a constant, gentle pressure to this area. This gives you a feeling of satiety (a feeling of fullness) on a smaller amount of food, therefore you eat less.

For additional information regarding LAP-BAND^®, please visit lapband.com.

For full safety information please talk with your doctor, or call 1-800-LAPBAND.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is revolutionizing the treatment of obesity and other gastrointestinal disorders by developing less invasive solutions for a whole new group of patients not seeking treatment today. Apollo is a global innovator pushing boundaries to bring new technologies and innovative products to markets in over 80 countries today. In particular, Apollo’s bariatric products fill the gap between non-surgical weight loss solutions and invasive surgeries, allowing physicians to do more for those patients who require more than drug therapy and dietary advice. For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

© 2015 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.